Jennison Associates
MLYS icon

Jennison Associates’s Mineralys Therapeutics MLYS Stock Holding History

Jennison Associates’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$34.3M Buy
1,266,174
+7,521
+0.6% +$221K 0.02% 267
2025
Q4 		$45.7M Buy
1,258,653
+882,307
+234% +$35.4M 0.03% 223
2025
Q3 		$14.3M Sell
376,346
-858,976
-70% -$18.6M 0.01% 352
2025
Q2 		$16.7M Sell
1,235,322
-743,711
-38% -$10.8M 0.01% 348
2025
Q1 		$31.4M Buy
1,979,033
+897,027
+83% +$10.3M 0.02% 269
2024
Q4 		$13.3M Buy
1,082,006
+385,726
+55% +$5.04M 0.01% 378
2024
Q3 		$8.43M Buy
696,280
+13,023
+2% +$158K 0.01% 400
2024
Q2 		$7.99M Buy
+683,257
New +$8.61M 0.01% 403
2023
Q3 		– Sell
-355,475
Closed -$6.06M – 587
2023
Q2 		$6.06M Hold
355,475
– – 0.01% 412
2023
Q1 		$5.57M Buy
+355,475
New +$5.98M 0.01% 434

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Jennison Associates's MLYS Position: Q1 2026 in Review

Jennison Associates increased its Mineralys Therapeutics (MLYS) stake by 0.6% in Q1 2026, buying an estimated $221K and bringing the position to 1,266,174 shares worth $34.3M. The position accounts for 0.02% of the portfolio, ranked #267.

Jennison Associates first reported a position in MLYS in Q1 2023 and has held it in 10 quarters since. The position peaked at $45.7M in Q4 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • Jennison Associates held 1,266,174 shares of Mineralys Therapeutics worth $34.3M as of Q1 2026.
  • Jennison Associates bought 7,521 Mineralys Therapeutics shares in Q1 2026, an estimated $221K.
  • Mineralys Therapeutics made up 0.02% of Jennison Associates's portfolio in Q1 2026, its #267 holding.
  • Jennison Associates first reported a position in Mineralys Therapeutics in Q1 2023 and has held it in 10 quarters since.
  • Jennison Associates's Mineralys Therapeutics position peaked at $45.7M in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Jennison Associates's 13F filing for Q1 2026, filed 6 May 2026.